Diuretic Testing in Chronic Kidney Disease
ConditionKidney Disease, Chronic
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasmus Medical Center
About this trial
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are:
Does a worse result of a diuretic test predict the progression of chronic kidney disease?
If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney.
Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.
Eligibility criteria
Qualifiers
CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit
Disqualifiers
Known intolerance or allergy to the diuretics
Current systemic chemotherapy for malignancy
Kidney transplant recipient
Use of calcineurin-inhibitors
Trial design
Treatments tested in this trial
- Diuretic Testing
Treatment groups
86 Participants
are divided into 2 treatment groupsSponsors and collaborators
Erasmus Medical Center
Lead sponsor
European Research Council
Collaborator
Source ClinicalTrials.gov